Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: A population-based cohort study in Italy

BMJ Open

Volumn 7, Issue 3, 2017, Pages

  Trotta, Francesco ^a   Belleudi, Valeria ^a   Fusco, Danilo ^a   Amato, Laura ^a   Mecozzi, Alessandra ^b   Mayer, Flavia ^a   Sansone, Massimo ^b   Davoli, Marina ^a   Addis, Antonio ^a  

^a DEPARTMENT OF EPIDEMIOLOGY   (Italy)

^b The Lazio Region   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT;

ADULT; AGED; ARTICLE; BLOOD DYSCRASIA; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL PRACTICE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; DRUG SAFETY; FEMALE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MORTALITY; POPULATION RESEARCH; RISK BENEFIT ANALYSIS; ANEMIA; BLOOD; CAUSE OF DEATH; COMPARATIVE STUDY; ERYTHROPOIESIS; NEOPLASM; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; TREATMENT OUTCOME;

ANEMIA; BIOSIMILAR PHARMACEUTICALS; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; EPOETIN ALFA; ERYTHROPOIESIS; FEMALE; HEMATINICS; HUMANS; ITALY; MALE; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 85015227757     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2016-011637     Document Type: Article

References (35)

1. Associazione Italiana di Oncologia Medica. Linee Guida Gestione della tossicità ematopoietica in oncologia. Milan, 2015: 50p. http://www.aiom.it/professionisti/documenti-scientifici/linee-guida/tossicit-ematopoietica/1,710,1
2. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012;2: 279-335.
3. Sistema Nazionale Linee Guida -Istituto Superiore di Sanità, Società Italiana di Nefrologia, Ministero della Salute. Linea Guida "Identificazione, prevenzione e gestione della Malattia Renale Cronica nell'adulto". Rome, 2012: 136p. http://www.snlg-iss.it/lgn-malattia-renale
4. Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 2008;13(Suppl 3): S33-6.
5. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology, American Society of Hematology. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010;28: 4996-5010.
6. National Comprehensive Cancer Network (NCCN). NCCN guidelines. Cancer-and chemotherapy-induced anemia (version 2.2016). USA, 2015: 50p. Available from: Http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
7. Greer JW, Milam RA, Eggers PW. Trends in use, cost, and outcomes of human recombinant erythropoietin, 1989-98. Health Care Financ Rev 1999;20: 55-62.
8. European Survey on Anaemia Management (ESAM). Nephrol Dial Transplant 2000;15(Suppl 4): S1-76.
9. Open database. European public assessment reports. London: The European Medicines Agency. (cited 2016 January 5). http://www. ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar-search.jsp&mid=WC0b01ac058001d124.
10. Dylst P, Vulto A, Simoens S. Barriers to the uptake of biosimilars and possible solutions: A Belgian case study. Pharmacoeconomics 2014;32: 681-91.
11. Rompas S, Goss T, Amanuel S, et al. Demonstrating value for biosimilars: A conceptual framework. Am Health Drug Benefits 2015;8: 129-39.
12. Italian Medicines Agency. The Medicines Utilisation Monitoring Centre (OsMed). National Report on Medicines use in Italy. Year 2014. Rome, 2015: 522. http://www.agenziafarmaco.gov.it/it/content/rapporti-osmed-luso-dei-farmaci-italia
13. Ingrasciotta Y, Giorgianni F, Bolcato J, et al. How much are biosimilars used in clinical practice? A retrospective Italian population-based study of erythropoiesis-stimulating agents in the years 2009-2013. BioDrugs 2015;29: 275-84.
14. Palmer SC, Saglimbene V, Mavridis D, et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: A network meta-analysis. Cochrane Database Syst Rev 2014;(12): CD010590.
15. Barosi G, Bosi A, Abbracchio MP, et al. Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica 2011;96: 937-42.
16. Rodriguez Garzotto A, Cortijo Casacajares S, Pernaut C, et al. Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: Comparisons from real-world clinical experience. J Blood Med 2014;5: 43-8.
17. Michallet M, Luporsi E, Soubeyran P, et al. BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: Results of the ORHEO observational study. BMC Cancer 2014;14: 503.
18. Michallet M, Losem C. Biosimilar epoetin zeta in oncology and haematology: Development and experience following 6 years of use. Acta Haematol 2016;135: 44-52.
19. Ebbers HC, Muenzberg M, Schellekens H. The safety of switching between therapeutic proteins. Expert Opin Biol Ther 2012;12: 1473-85.
20. Ebbers HC, Mantel-Teeuwisse AK, Moors EH, et al. Today's challenges in pharmacovigilance: What can we learn from epoetins? Drug Saf 2011;34: 273-87.
21. Dipartimento di Epidemiologia della Regione Lazio. Lo stato di salute della popolazione del Lazio 2010-2012. Roma, 2015. http://95.110.213.190/statosal-10-12/note-metod-pat.php?menu=s52
22. Diamond A, Jasjeet SS. Genetic matching for estimating causal effects: A general multivariate matching method for achieving balance in observational studies. Rev Econ Stat 2013;95: 932-45.
23. Krivoshiev S, Wizemann V, Czekalski S, et al. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Adv Ther 2010;27: 105-17.
24. Krivoshiev S, Todorov VV, Manitius J, et al., Epoetin Zeta Study Group. Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia. Curr Med Res Opin 2008;24: 1407-15.
25. Martin KJ, Epoetin Delta 3001 Study Group. Epoetin delta in the management of renal anaemia: Results of a 6-month study. Nephrol Dial Transplant 2007;22: 3052-4.
26. Milutinović S, Plavljanić E, Trkulja V. Comparison of two epoetin brands in anemic hemodialysis patients: Results of two efficacy trials and a single-dose pharmacokinetic study. Fundam Clin Pharmacol 2006;20: 493-502.
27. Spinowitz BS, Pratt RD, Epoetin Delta 2002 Study Group. Epoetin delta is effective for the management of anaemia associated with chronic kidney disease. Curr Med Res Opin 2006;22: 2507-13.
28. Goh BL, Ong LM, Sivanandam S, et al., Biogeneric EPO Study Group. Randomized trial on the therapeutic equivalence between Eprex and GerEPO in patients on haemodialysis. Nephrology (Carlton) 2007;12: 431-6.
29. Haag-Weber M, Vetter A, Thyroff-Friesinger U, et al. NJ-Study Group. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol 2009;72: 380-90.
30. Haag-Weber M, Eckardt KU, Hfrl WH, et al. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-A (HX575) in non-dialysis patients with renal anemia: A multi-center, randomized, double-blind study. Clin Nephrol 2012;77: 8-17.
31. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet 2009;373: 1532-42.
32. Hörbrand F, Bramlage P, Fischaleck J, et al. A population-based study comparing biosimilar versus originator erythropoiesisstimulating agent consumption in 6,117 patients with renal anaemia. Eur J Clin Pharmacol 2013;69: 929-36.
33. Weise M, Kurki P, Wolff-Holz E, et al. Biosimilars: The science of extrapolation. Blood 2014;124: 3191-6.
34. Schiestl M, Stangler T, Torella C, et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011;29: 310-12.
35. Schneider CK. Biosimilars in rheumatology: The wind of change. Ann Rheum Dis 2013;72: 315-18.